Publications and Presentations

Filter by:

All Molecules

Etrumadenant (AB928)

Quemliclustat (AB680)

Domvanalimab (AB154)

Zimberelimab (AB122)

AB308 (TIGIT)

AB521 (HIF-2α)

AB598 (CD39)

AB801 (AXL)

HPK1

Discovery Pipeline

All Conferences

AACR

Immunology 2022

ACS

ASCO

FOCiS

ASCPT

ENA

ESMO

IKCS

Keystone

SABCS

SITC

Manuscripts

MCI

Sort by:

Date

Conference

No results found

June 24-27, 2023

AACR Special Conference: Advances in Kidney Cancer Research

Targeting Hypoxia Inducible Factor (HIF)-2α With AB521, a Novel and Potent Small Molecule HIF-2α Inhibitor, for the Treatment of Clear Cell Renal Cell Carcinoma

Paul G. Foster, et al.

April 14-19, 2023

American Association for Cancer Research (AACR)

Characterization of AB598, a Therapeutic Anti-Human CD39 Antibody for the Treatment of Cancer

Amy E. Anderson, et al.

April 14-19, 2023

American Association for Cancer Research (AACR)

AB801 is a Highly Potent and Selective AXL Kinase Inhibitor that Demonstrates Significant Anti-Tumor Activity

Susan L Paprcka, et al.

March 26-30, 2023

American Chemical Society Spring Meeting

Discovery and characterization of potent and selective AXL receptor tyrosine kinase inhibitors

Corinne N. Foley, et al.

March 26-30, 2023

American Chemical Society Spring Meeting

Discovery and characterization of orally bioavailable, potent, and selective small-molecule AXL kinase inhibitors for cancer therapy

Shiwei Qu, et al.

March 22-24, 2023

American Society for Clinical Pharmacology & Therapeutics (ASCPT)

Use of a population pharmacokinetic modelling and simulation approach to identify flat doses of domvanalimab in phase 3 studies

Ayyappa Chaturvedula, et al.

March 22-24, 2023

American Society for Clinical Pharmacology & Therapeutics (ASCPT)

Limited drug interaction supported by a clinical drug interaction study and physiologically based pharmacokinetic modeling of etrumadenant (AB928), a novel dual adenosine receptor antagonist, under coadministration with a strong CYP3A4 and p-glycoprotein inhibitor (itraconazole) in healthy participants

Lian Zhou, et al.

March 6-8, 2023

ESMO Targeted Anticancer Therapies Congress

Inhibition of HIF-2α-dependent transcription with small molecule inhibitors may provide therapeutic benefit beyond renal cell carcinoma

Kelsey E. Gauthier, et al.

January 28-31, 2023

61st Midwinter Conference of Immunologists at Asilomar

Rationale for the combination of AB598, a CD39 blocking antibody, and chemotherapy for the treatment of solid tumors

Kaustubh Parashar, et al.

December 20, 2022

ASCO Plenary Series

ARC-7: Randomized phase 2 study of domvanalimab + zimberelimab ± etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC)

Melissa Johnson, et al.

November 8-12, 2022

Society for Immunotherapy of Cancer (SITC)

HPK1 inhibition relieves suppression downstream of TCR activation to drive enhanced cytokine production, an effect that is further enhanced by immune checkpoint blockade

Rajesh Singh, et al.

November 8-12, 2022

Society for Immunotherapy of Cancer (SITC)

The anti-tumor efficacy of immunogenic chemotherapy is enhanced by the dual A2aR/A2bR antagonist etrumadenant, relieving the necessity for a full chemotherapy regimen.

Daniel DiRenzo, et al.

November 8-12, 2022

Society for Immunotherapy of Cancer (SITC)

AB598, a therapeutic anti-human CD39 antibody, binds and inhibits CD39 enzymatic activity in vivo to promote anti-tumor immunity

Kaustubh Parashar, et al.

October 26-28, 2022

EORTC-NCI-AACR (ENA) Molecular Targets and Cancer Therapeutics Symposium

HIF-2α inhibitor AB521 modulates erythropoietin levels in healthy volunteers following a single oral dose

Kai H. Liao, et al.

October 26-28, 2022

EORTC-NCI-AACR (ENA) Molecular Targets and Cancer Therapeutics Symposium

AB801 is a potent and selective AXL inhibitor that demonstrates significant anti-tumor activity in combination with standard of care therapeutics

Susan L. Paprcka, et al.

October 26-28, 2022

EORTC-NCI-AACR (ENA) Molecular Targets and Cancer Therapeutics Symposium

Discovery and characterization of potent and selective AXL receptor tyrosine kinase inhibitor AB801

Dillon H. Miles, et al.

October 21-24, 2022

AACR Tumor Immunology & Immunotherapy Symposium

HPK1 inhibition enhances T cell activation and relieves the immunosuppressive effects of extracellular substances found in the tumor microenvironment

Bindi Patel, et al.

October 21-24, 2022

AACR Tumor Immunology & Immunotherapy Symposium

AB598, a therapeutic anti-CD39 antibody, elevates ATP and increases immunogenicity in the tumor microenvironment

Kaustubh Parashar, et al.

June 21-24, 2022

Federation of Clinical Immunology Societies (FOCiS)

Anti-TIGIT Antibodies Promote Immune Activation in Combination with Immunotherapeutic Agents

Dana Piovesan, et al.

June 21-24, 2022

Federation of Clinical Immunology Societies (FOCiS)

Inhibiting TIGIT to Promote Anti-Tumor Immunity

Dana Piovesan, et al.

June 2022

Molecular Cancer Therapeutics

Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity

Dana Piovesan, et al.

May 6-10, 2022

Immunology 2022

Anti-TIGIT Antibodies Promote Immune Activation Relevant to Targeting Stem-like and Tumor-specific T Cells in Combination With Anti-PD-1

Kelsey E. Gauthier, et al.

April 22-24, 2022

International Kidney Cancer Symposium (IKCS)

AB521 is a Novel and Potent Clinical-Stage HIF-2a Inhibitor for the Treatment of Renal Cell Carcinoma

Kelsey E. Gauthier, et al.

April 8-13, 2022

American Association for Cancer Research (AACR)

Dual A2aR/A2bR antagonism with etrumadenant (AB928) eliminates the suppressive effects of adenosine on immune and cancer cells in the tumor microenvironment

Sachie Marubayashi, et al.

April 8-13, 2022

American Association for Cancer Research (AACR)

Inhibition of CD39 Results in Elevated ATP and Activation of Myeloid Cells to Promote Anti-Tumor Immunity

Christine Bowman, et al.

April 8-13, 2022

American Association for Cancer Research (AACR)

HPK1 inhibition enhances T cell activation and relieves the immunosuppressive phenotype of inhibitory signals found in the tumor microenvironment

Rajesh Singh, et al.

March 16-18, 2022

American Society for Clinical Pharmacology & Therapeutics (ASCPT)

Population Pharmacokinetics of Zimberelimab (AB122) and Dose Justification by Model Informed Drug Development (MIDD) Approach

Xiaoying Yu, et al.

March 16-18, 2022

American Society for Clinical Pharmacology & Therapeutics (ASCPT)

Population Pharmacokinetics and Pharmacodynamics of Etrumadenant (AB928) in Healthy Volunteers and Cancer Patients

Huali Wu, et al.

March 16-18, 2022

American Society for Clinical Pharmacology & Therapeutics (ASCPT)

A Mechanistic Pharmacokinetic-Pharmacodynamic (PK-PD) Model of Quemliclustat (AB680), a Small-Molecule Inhibitor of CD73, in Healthy Volunteers and Patients with Gastrointestinal Malignancies

Kai H. Liao, et al.

March 7-8, 2022

ESMO Targeted Anticancer Therapies Congress

AB521, a Clinical-Stage, Potent, and Selective Hypoxia-Inducible Factor (HIF)-2⍺ Inhibitor, for the Treatment of Renal Cell Carcinoma

Kenneth Lawson, et al.

November 10-14, 2021

Society for Immunotherapy of Cancer (SITC)

AB308 is an Anti-TIGIT Antibody That Enhances Immune Activation and Anti-Tumor Immunity Alone and in Combination With Other I-O Therapeutic Agent

Dana Piovesan, et al.

October 7-10, 2021

AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

AB521 potently and selectively inhibits pro-tumorigenic gene transcription by Hypoxia-Inducible Factor (HIF)-2⍺ in vitro and in vivo

Dana Piovesan, et al.

October 7-10, 2021

AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Potent and selective AXL tyrosine kinase inhibition demonstrates significant anti-tumor efficacy in combination with standard of care therapeutics in preclinical models

Susan L Paprcka, et al.

June 4-8, 2021

American Society of Clinical Oncology (ASCO) Annual Meeting

ARC-6: A Phase 1b/2, Open-Label, Randomized Platform Study to Evaluate Efficacy and Safety of Etrumadenant (AB928)-Based Treatment Combinations in Patients with Metastatic Castrate-Resistant Prostate Cancer

Sumit K. Subudhi, et al.

April 9-14, 2021

Annual Meeting of the American Association of Cancer Research (AACR)

Discovery and characterization of AB521, a novel, potent, and selective hypoxia-inducible factor (HIF)-2⍺ inhibitor

Kenneth V. Lawson, et al.

April 9-14, 2021

Annual Meeting of the American Association of Cancer Research (AACR)

ARC-3: Updated results of Etrumadenant (AB928) + mFOLFOX-6 in patients with metastatic colorectal cancer

M. Cecchini, et al.

January 15-17, 2021

2021 Gastrointestinal Cancers Symposium (ASCO GI)

ARC-8: Phase 1/1b Study to Evaluate Safety and Tolerability of AB680 + Chemotherapy + Zimberelimab (AB122) in Patients with Treatment-Naive Metastatic Pancreatic Adenocarcinoma

GA Manji, et al.

January 15-17, 2021

2021 Gastrointestinal Cancers Symposium (ASCO GI)

ARC-9: Phase 1b/2 Study to Evaluate Etrumadenant (AB928)-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer

M.Cecchini, et al.

December 8-11, 2020

San Antonio Breast Cancer Symposium (SABCS)

ARC-2: Efficacy and Safety of Etrumadenant (AB928) + Pegylated Liposomal Doxorubicin (PLD) ± Eganelisib (IPI-549) in Participants with Metastatic Ovarian and Triple Negative Breast Cancer

J Sachdev, et al.

November 9, 2020

Society for Immunotherapy of Cancer (SITC)

Emerging Insights on the Association of Tumor Molecular Phenotype with Clinical Benefit in Metastatic Colorectal Cancer (mCRC) Subjects Treated with AB928 + Modified FOLFOX-6 (mFOLFOX-6)

Akshata R Udyavar, et al.

November 9, 2020

Society for Immunotherapy of Cancer (SITC)

Potent and Selective Inhibition of AXL Receptor Tyrosine Kinase for the Treatment of Cancer

Susan L. Paprcka, et al.

November 9, 2020

Society for Immunotherapy of Cancer (SITC)

Novel, Potent, and Selective Inhibitors of Hypoxia-Inducible Factor (HIF)-2α Reverse Pro-tumorigenic Transcriptional Programming in Cancer, Stromal, and Immune Cells

Dana Piovesan, et al.

October 24-25, 2020

32nd EORTC-NCI-AACR (ENA) Symposium

Discovery and Characterization of Potent and Selective AXL Receptor Tyrosine Kinase Inhibitors for Cancer Therapy

Dillon H. Miles, et al.

October 24-25, 2020

32nd EORTC-NCI-AACR (ENA) Symposium

Discovery and Characterization of Novel, Potent, and Selective Hypoxia-Inducible Factor (HIF)-2a Inhibitors

Kenneth V Lawson, et al.

September 19-21, 2020

European Society for Medical Oncology (ESMO) Congress

ARC-4: Efficacy and Safety of Etrumadenant (AB928) plus Carboplatin, Pemetrexed and a PD-1 Antibody in Participants with Metastatic Non-Small Cell Lung Cancer

A Spira , et al.

September 19-21, 2020

European Society for Medical Oncology (ESMO) Congress

ARC-6: A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of Etrumadenant (AB928)-Based Treatment Combinations in Patients with Metastatic Castrate-Resistant Prostate Cancer

SK Subudhi , et al.

September 19-21, 2020

European Society for Medical Oncology (ESMO) Congress

ARC-7: A Phase 2 Study to Evaluate the Safety and Efficacy of Zimberelimab Monotherapy and Domvanalimab (AB154) + Zimberelimab +/- Etrumadenant (AB928) in Front-Line, PD-L1-High Expressing, Non-Small Cell Lung Cancer

A Chaudhry, et al.

June 22-24, 2020

Annual Meeting of the American Association of Cancer Research (AACR)

Audio: Efficacy and safety of etrumadenant plus modified FOLFOX-6 in participants with metastatic colorectal cancer: initial results at the recommended dose for expansion (ARC-3).

M Cecchini, et al.

Play Audio - 4:56

June 22-24, 2020

Annual Meeting of the American Association of Cancer Research (AACR)

Poster: Efficacy and safety of etrumadenant plus modified FOLFOX-6 in participants with metastatic colorectal cancer: initial results at the recommended dose for expansion (ARC-3).

M Cecchini, et al.

February 13-15, 2020

American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium

A phase 1b/2, open-label, platform study evaluating the efficacy and safety of etrumadenant-based treatment combinations in participants with metastatic castrate resistant prostate cancer (ARC-6).

Wise DR, et al.

January 23-25, 2020

Gastrointestinal Cancers Symposium (ASCO)

A phase 1 study to evaluate the safety and tolerability of AB680 combination therapy in participants with gastrointestinal malignancies (ARC-8).

Bendell J, et al.

January 19-24, 2020

Keystone Symposia Conference

Selective inhibition of hypoxia-inducible factor (HIF)-2α for the treatment of cancer.

Piovesan D, et al.

November 6-10, 2019

Society for Immunotherapy of Cancer (SITC)

A_2bR contributes to adenosine-mediated immunosuppression, which is relieved by the dual A_2a/A_2b antagonist etrumadenant.

DiRenzo D, et al.

November 6-10, 2019

Society for Immunotherapy of Cancer (SITC)

Phase 1 safety trial in healthy volunteers of Quemliclustat (AB680), a small molecule inhibitor of CD73 and rationale for combination therapy in patients with gastrointestinal malignancies.

Ashok D, et al.

November 6-10, 2019

Society for Immunotherapy of Cancer (SITC)

Characterization of domvanalimab, a humanized, non-depleting α-TIGIT antibody undergoing clinical evaluation in subjects with advanced solid tumors.

Anderson AE, et al.

November 6-10, 2019

Society for Immunotherapy of Cancer (SITC)

Targeting immune-suppressive myeloid cell pathways for the treatment of cancer.

Banuelos J, et al.

October 26-30, 2019

AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics

Novel, potent, and selective hypoxia-inducible factor-2α (HIF-2α) antagonists.

Gauthier KES, et al.

September 27 – October 1, 2019

European Society for Medical Oncology (ESMO) Congress

Phase 1 evaluation of etrumadenant, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies.

Powderly J, et al.

July 23, 2019

Biochemistry

An exceptionally potent inhibitor of human CD73.

Bowman CE, et al.

May 31 – June 4, 2019

American Society of Clinical Oncology (ASCO) Annual Meeting

Etrumadenant, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients with advanced tumors: preliminary results from ongoing phase 1 studies.

Powderly J, et al.

March 29 – April 3, 2019

Annual Meeting of the American Association of Cancer Research (AACR)

Altered pan-Ras pathway and activating mutations in EGFR result in elevated CD73 in multiple cancers.

Udyavar A, et al.

March 29 – April 3, 2019

Annual Meeting of the American Association of Cancer Research (AACR)

Methods for assessment of the “adenosine fingerprint” in clinical trials of etrumadenant.

DiRenzo D, et al.

March 29 – April 3, 2019

Annual Meeting of the American Association of Cancer Research (AACR)

Receptor occupancy and neo-epitope specific T-cell repertoires in patients with solid tissue tumors following anti-PD-1 therapy.

Ashok D, et al.

March 29 – April 3, 2019

Annual Meeting of the American Association of Cancer Research (AACR)

Characterization of domvanalimab, a humanized α-TIGIT antibody, for use in combination therapies.

Anderson AE, et al.

March 29 – April 3, 2019

Annual Meeting of the American Association of Cancer Research (AACR)

Longitudinal monitoring of neoepitope-specific T cell repertoires in patient blood following cancer immunotherapy.

Peng S, et al.

March 29 – April 3, 2019

Annual Meeting of the American Association of Cancer Research (AACR)

AB474, a potent orally bioavailable inhibitor of arginase, for the treatment of cancer.

Eckard SC, et al.

March 29 – April 3, 2019

Annual Meeting of the American Association of Cancer Research (AACR)

Inhibiting CD73 and KRAS enhances the effect of anti-PD-1 therapy in a KRAS^G12C/TP53^R172H/+ pancreatic cancer model.

Le TM, et al.

March 10-14, 2019

Keystone Symposia Conference C2

Oncogene-driven regulation of adenosine pathway expression in multiple cancers.

Udyavar AR, et al.

December 19, 2018

Investigational New Drugs

Safety, tolerability, and pharmacology of etrumadenant, a novel dual adenosine receptor antagonist, in a randomized, phase 1 trial in healthy volunteers.

Seitz L, et al.

November 7-11, 2018

Society for Immunotherapy of Cancer (SITC)

Preclinical characterization of domvanalimab, a fully humanized anti-TIGIT antibody, for use in combination therapies.

Anderson AE, et al.

November 7-11, 2018

Society for Immunotherapy of Cancer (SITC)

Development of a robust, simplified method to measure receptor occupancy in peripheral blood from patients treated with a novel anti-PD-1 agent, AB122.

Ashok D, et al.

November 7-11, 2018

Society for Immunotherapy of Cancer (SITC)

Development of biomarkers to assess adenosine generation & activity in support of clinical trials conducted with the adenosine receptor antagonist etrumadenant.

DiRenzo D, et al.

November 7-11, 2018

Society for Immunotherapy of Cancer (SITC)

Selection of optimized drug candidates, dosing regimen, pharmacodynamic endpoints, tumor types, and biomarkers for translating inhibition of the adenosine pathway into effective anti-tumor activity.

Jaen J, et al.

Combining To Cure®

The molecules and their uses are investigational. Arcus has not received approval from any regulatory authority for any use globally, and the safety and efficacy of these molecules has not been established.

Publications

Explore More